Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602138 | 0.85 | JAK2 (0.46) | JAK2JAK1ROCK1HDAC3HDAC4 | |
| SCHEMBL606136 | 0.81 | JAK2 (0.45) | JAK2JAK1ROCK1HDAC3HDAC4 | |
| SCHEMBL27696421 | 0.80 | HRH3 (0.44) | JAK2JAK1ROCK1ADORA2AADORA1 | |
| SCHEMBL604263 | 0.80 | HRH4 (0.49) | JAK2JAK1ROCK1HDAC3HDAC4 | |
| SCHEMBL603457 | 0.80 | JAK1 (0.47) | JAK2JAK1ROCK1HDAC3HDAC4 | |
| SCHEMBL13338280 | 0.79 | HRH4 (0.56) | JAK2JAK1HDAC3HDAC4HDAC1 | |
| SCHEMBL13338281 | 0.78 | HRH4 (0.57) | JAK2JAK1HRH4 | |
| SCHEMBL604488 | 0.78 | JAK2 (0.41) | JAK2JAK1ROCK1PPARGPPARA | |
| SCHEMBL605806 | 0.77 | JAK1 (0.44) | JAK2JAK1ROCK1ADORA2AADORA1 | |
| SCHEMBL13338282 | 0.76 | HRH4 (0.49) | JAK2JAK1PPARGPPARAADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737297-B1 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-19 | — | — | EP | claimed |
| US-7956071-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | claimed |
| EP-1737297-A4 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-15 | — | — | EP | claimed |
| US-20070173512-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | claimed |
| EP-1737297-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-03 | — | — | EP | claimed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | claimed |
| WO-2005092066-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | WO | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20070173512-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| EP-1737297-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | disclosed |
| WO-2005092066-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173512-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | JAK2 453/4885JAK1 1700/4885ROCK1 2023/4885 |
| US-20070149541-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | JAK2 453/4885JAK1 1700/4885ROCK1 2023/4885 |
| US-20050261309-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | JAK2 453/4885JAK1 1700/4885ROCK1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.